Pharma companies elevate manufacturing execution systems to strategic assets

capgemini.com

Pharma companies are evolving Manufacturing Execution Systems (MES) from compliance tools to strategic assets. This shift aims to unlock greater business impact beyond initial implementation and technical functionality. Leading companies are developing strategies to maximize MES value and close the post-launch performance gap.


With a significance score of 2.4, this news ranks in the top 21% of today's 30110 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Pharma companies elevate manufacturing execution systems to strategic assets | News Minimalist